Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) to a sell rating in a research note issued to investors on Monday.

Separately, Needham & Company LLC reissued a hold rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, April 11th.

Lexicon Pharmaceuticals Trading Down 4.4 %

Shares of NASDAQ LXRX opened at $1.62 on Monday. The firm has a 50 day moving average price of $2.39 and a two-hundred day moving average price of $1.70. The stock has a market cap of $398.91 million, a P/E ratio of -2.02 and a beta of 1.27. Lexicon Pharmaceuticals has a 52-week low of $0.92 and a 52-week high of $3.79. The company has a debt-to-equity ratio of 1.07, a quick ratio of 5.58 and a current ratio of 5.60.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.03. The company had revenue of $0.70 million for the quarter, compared to analysts’ expectations of $0.68 million. Lexicon Pharmaceuticals had a negative net margin of 14,573.20% and a negative return on equity of 138.54%. As a group, equities analysts forecast that Lexicon Pharmaceuticals will post -0.71 EPS for the current year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

A number of institutional investors have recently modified their holdings of LXRX. BVF Inc. IL raised its stake in Lexicon Pharmaceuticals by 22.2% during the fourth quarter. BVF Inc. IL now owns 24,435,632 shares of the biopharmaceutical company’s stock worth $37,387,000 after buying an additional 4,440,300 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Lexicon Pharmaceuticals by 34.0% in the 3rd quarter. Vanguard Group Inc. now owns 5,256,288 shares of the biopharmaceutical company’s stock worth $12,614,000 after acquiring an additional 1,334,318 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Lexicon Pharmaceuticals by 27.4% in the 3rd quarter. BlackRock Inc. now owns 5,760,000 shares of the biopharmaceutical company’s stock valued at $13,823,000 after purchasing an additional 1,240,171 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Lexicon Pharmaceuticals in the 4th quarter valued at about $1,194,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Lexicon Pharmaceuticals during the 3rd quarter valued at about $1,155,000. 74.70% of the stock is owned by institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.